(NBC NEWS) — An experimental drug is showing promise in the treatment of migraines.
Nearly 1,700 patients were involved in the phase 3 study.
Among those who were given the drug Ubrogepant, nearly 22-percent were free of migraine pain symptoms two hours later.
That is compared to the 14-percent who were on the placebo.
An FDA decision on approval is expected next month.